Cervical Cancer ScreeningNCG-ComplianceNCT07290972
Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
An observational study of Cervical Cancer Screening and Gynecologic Cancers, run by Tata Memorial Hospital at 2 sites in India.
Trial summary
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Cervical Cancer Screening, Gynecologic Cancers, Treatment Compliance
- What is being tested?
- Not applicable- observational study
- How many people
- 618 participants
- Where
- 2 sitesIndia
- Study dates
- 1 Feb 2021to 31 Mar 2026
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned. Furthermore any cases referred to the institution for brachytherapy alone will also be included.
The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.
Furthermore any cases referred to the institution for brachytherapy alone will also be included.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
India2 sites, 2 recruiting
- Recruiting
Tata Memorial Hospital
Mumbai, Maharashtra, 400012
Dr. Supriya Chopra, MD, 9930958309, supriyasastri@gmail.com
- Recruiting
Tata Memorial Hospital
Mumbai, Maharashtra, 400012
Dr Supriya Chopra, MD, +91 9930958309, supriyasastri@gmail.com
About this study
Official title: Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+/- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and/or concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.
As a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.
Read more
Each of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.
Those centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and /or concurrent chemotherapy over a period of 6 months.
Read the detailed description
Investigator intend to use electronic case record form (e-CRF) created using on line portal (google e-forms) wherein details of patients treated within the 6 month period will be captured. Google e-CRF will be available to all participating centres free of charge and has ease of access for filling details on both computer, tablets or mobile phone platforms. The e-form is user friendly and provides automated excel output and basic trends of responses and is ideal to be used across busy departments and low resource settings.
To maintain data security, no patient identifying information will be collected. Each institution will be provided an institution id and name identifiers will not be used. Similarly a code will be generated for each of the patient and details of that code will remain with the parent institution.
- Being tested
- Not applicable- observational study
- Keywords
- Cervical cancer, Cancer, Recurrence, Treatment, Compliance, Chemoradiotherapy
- Medical subject headings
- Patient Compliance, Uterine Cervical Neoplasms, Neoplasms, Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Not applicable- observational studyOther
Compliance to Cervical Cancer Chemoradiation treatment guidelines
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with Cervical Cancer | Patients diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy planned. Receives: Other: Not applicable- observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
report on institutional compliance to National Cancer Grid cervical cancer guidelines for chemo-radiation.
To report praportion of patients with No deviation, Major \& Minor Deviation and unacceptable deviation for chemoradiation guidlines.
Measured: 3 Months
Secondary outcomes (3)
To report on factors impacting compliance to standard guidelines
Measured: 3years
To report adequacy of infrastructural and manpower requirements for optimal treatment of cervical cancer in NCG centres and corresponding state of origin
Measured: 3 years
To compute relative risk of suboptimal treatment for cervical cancer in reference to infrastructural and manpower deficits
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start1 Feb 2021
- Primary completion31 Mar 2026 (estimated)
- Study completion31 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Cervical Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 618 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Tata Memorial Hospital
- Sponsor type
- Other government
- Collaborators
- Post Graduate Institute of Medical Education and Research, Chandigarh, MNJ Institute of Oncology and Regional Cancer Center, Christian Medical College, Vellore, India
- Responsible party
- Principal investigator, Supriya Sastri (chopra), Tata Memorial Centre
- Investigators
- Dr. Supriya Chopra, MD, Principal investigator, ACTREC, Tata Memorial Centre, Navi Mumbai India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07290972
- Sponsor's protocol ID
- TMC IEC III 900537
- Acronym
- NCG-Compliance
- Status last verified
- Jan 2026
- First submitted
- 21 Aug 2025
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Dr. V. K. Srivastava, Dr Tanvir Kaur, Dr. S Shrisvastava () CONSENSUS DOCUMENT FOR THE MANAGEMENT OF CANCER CERVIX, Available at: https://www.icmr.nic.in > sites > default > files > reports > Cervix Cance (Accessed: 12th December 2019).
IAEA staffing estimator. http://nucleus.iaea.org/HHW/RadiationOncology/making the case for radiotherapy in your country/role of radiotherapy in cancer care/radiotherapy is a cost effective system which needs balance/index.html.
IPEM recommendations for the provision of physics services to radiotherapy. http://ipem.ac.uk/portals/0/documents/recommendations.
Budiharto T, Musat E, Poortmans P, Hurkmans C, Monti A, Bar-Deroma R, Bernstein Z, Tienhoven Gv, Collette L, Duclos F, Davis B, Aird E; EORTC Radiation Oncology Group. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol. 2008 Sep;88(3):403-10. doi: 10.1016/j.radonc.2008.05.013. Epub 2008 Jun 4.
PubMed 18538427International Atomic Energy Agency. Planning national radiotherapy services: a practical tool. IAEA human health series number 14. Vienna International Atomic Energy Agency;2010. ISBN 978-92-0-1059 10-9.
Nandakumar A, Kishor Rath G, Chandra Kataki A, Poonamalle Bapsy P, Gupta PC, Gangadharan P, Mahajan RC, Nath Bandyopadhyay M, Kumaraswamy, Vallikad E, Visweswara RN, Selvaraj Roselind F, Sathishkumar K, Daniel Vijaykumar D, Jain A, Lakshminarayana Sudarshan K. Concurrent Chemoradiation for Cancer of the Cervix: Results of a Multi-Institutional Study From the Setting of a Developing Country (India). J Glob Oncol. 2015 Sep 23;1(1):11-22. doi: 10.1200/JGO.2015.000877. eCollection 2015 Oct.
PubMed 28804767Grover S, Gudi S, Gandhi AK, Puri PM, Olson AC, Rodin D, Balogun O, Dhillon PK, Sharma DN, Rath GK, Shrivastava SK, Viswanathan AN, Mahantshetty U. Radiation Oncology in India: Challenges and Opportunities. Semin Radiat Oncol. 2017 Apr;27(2):158-163. doi: 10.1016/j.semradonc.2016.11.007. Epub 2016 Nov 14.
PubMed 28325242Banerjee S, Mahantshetty U, Shrivastava S. Brachytherapy in India - a long road ahead. J Contemp Brachytherapy. 2014 Oct;6(3):331-5. doi: 10.5114/jcb.2014.45761. Epub 2014 Oct 6.
PubMed 25337139Gandhi AK, Sharma DN, Julka PK, Rath GK. Attitude and practice of brachytherapy in India: a study based on the survey amongst attendees of Annual Meeting of Indian Brachytherapy Society. J Contemp Brachytherapy. 2015 Dec;7(6):462-8. doi: 10.5114/jcb.2015.55666. Epub 2015 Nov 17.
PubMed 26816503Mittal P, Chopra S, Pant S, Mahantshetty U, Engineer R, Ghosh J, Gupta S, Ghadi Y, Menachery S, Swamidas J, Gurram L, Shrivastava SK. Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy? J Glob Oncol. 2018 Jul;4:1-9. doi: 10.1200/JGO.18.00028.
PubMed 30085892Mahantshetty U, Krishnatry R, Hande V, Jamema S, Ghadi Y, Engineer R, Chopra S, Gurram L, Deshpande D, Shrviastava S. Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):608-617. doi: 10.1016/j.ijrobp.2017.06.010. Epub 2017 Jun 20.
PubMed 29280456Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. J ICRU. 2013 Apr;13(1-2):NP. doi: 10.1093/jicru/ndw027. No abstract available.
PubMed 27335496Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Segedin B, Jurgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016 Sep;120(3):428-433. doi: 10.1016/j.radonc.2016.03.011. Epub 2016 Apr 29.
PubMed 27134181Potter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jurgenliemk-Schulz I; EMBRACE Collaborative Group. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60. doi: 10.1016/j.ctro.2018.01.001. eCollection 2018 Feb.
PubMed 29594251Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, Gulia S, Kumar N, Shylasree TS, Gawade R, Kembhavi Y, Gaikar M, Menon S, Thakur M, Shrivastava S, Badwe R. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018 Jun 1;36(16):1548-1555. doi: 10.1200/JCO.2017.75.9985. Epub 2018 Feb 12.
PubMed 29432076
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
- ClinicalTrials.gov ID
- NCT07290972
- Acronym / sponsor ID
- NCG-Compliance / TMC IEC III 900537
- Keywords
- Cervical cancer, Cancer, Recurrence, Treatment, Compliance, Chemoradiotherapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 618 participants (estimated)
- Lead sponsor
- Tata Memorial HospitalOther government
- Collaborators
- Post Graduate Institute of Medical Education and Research, Chandigarh, MNJ Institute of Oncology and Regional Cancer Center, Christian Medical College, Vellore, India
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 31 Mar 2026 (estimated)
- Study completion
- 31 Mar 2026 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+/- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and/or concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.
As a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.
Each of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.
Those centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and /or concurrent chemotherapy over a period of 6 months.
Detailed description
Investigator intend to use electronic case record form (e-CRF) created using on line portal (google e-forms) wherein details of patients treated within the 6 month period will be captured. Google e-CRF will be available to all participating centres free of charge and has ease of access for filling details on both computer, tablets or mobile phone platforms. The e-form is user friendly and provides automated excel output and basic trends of responses and is ideal to be used across busy departments and low resource settings.
To maintain data security, no patient identifying information will be collected. Each institution will be provided an institution id and name identifiers will not be used. Similarly a code will be generated for each of the patient and details of that code will remain with the parent institution.
Study design
- Observational model
- Case only
- Time perspective
- Other
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with Cervical Cancer | – | Other: Not applicable- observational studyPatients diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy planned. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned. Furthermore any cases referred to the institution for brachytherapy alone will also be included.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Not applicable- observational studyCompliance to Cervical Cancer Chemoradiation treatment guidelines | Other | Patients diagnosed with Cervical Cancer |
Primary outcome
report on institutional compliance to National Cancer Grid cervical cancer guidelines for chemo-radiation.
Time frame: 3 Months
To report praportion of patients with No deviation, Major \& Minor Deviation and unacceptable deviation for chemoradiation guidlines.
3 secondary outcomes
To report on factors impacting compliance to standard guidelines
Time frame: 3years
To report adequacy of infrastructural and manpower requirements for optimal treatment of cervical cancer in NCG centres and corresponding state of origin
Time frame: 3 years
To compute relative risk of suboptimal treatment for cervical cancer in reference to infrastructural and manpower deficits
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- BackgroundDr. V. K. Srivastava, Dr Tanvir Kaur, Dr. S Shrisvastava () CONSENSUS DOCUMENT FOR THE MANAGEMENT OF CANCER CERVIX, Available at: https://www.icmr.nic.in > sites > default > files > reports > Cervix Cance (Accessed: 12th December 2019).
- BackgroundIAEA staffing estimator. http://nucleus.iaea.org/HHW/RadiationOncology/making the case for radiotherapy in your country/role of radiotherapy in cancer care/radiotherapy is a cost effective system which needs balance/index.html.
- BackgroundIPEM recommendations for the provision of physics services to radiotherapy. http://ipem.ac.uk/portals/0/documents/recommendations.
- Background: PubMed 18538427Budiharto T, Musat E, Poortmans P, Hurkmans C, Monti A, Bar-Deroma R, Bernstein Z, Tienhoven Gv, Collette L, Duclos F, Davis B, Aird E; EORTC Radiation Oncology Group. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol. 2008 Sep;88(3):403-10. doi: 10.1016/j.radonc.2008.05.013. Epub 2008 Jun 4.
- BackgroundInternational Atomic Energy Agency. Planning national radiotherapy services: a practical tool. IAEA human health series number 14. Vienna International Atomic Energy Agency;2010. ISBN 978-92-0-1059 10-9.
- Background: PubMed 28804767Nandakumar A, Kishor Rath G, Chandra Kataki A, Poonamalle Bapsy P, Gupta PC, Gangadharan P, Mahajan RC, Nath Bandyopadhyay M, Kumaraswamy, Vallikad E, Visweswara RN, Selvaraj Roselind F, Sathishkumar K, Daniel Vijaykumar D, Jain A, Lakshminarayana Sudarshan K. Concurrent Chemoradiation for Cancer of the Cervix: Results of a Multi-Institutional Study From the Setting of a Developing Country (India). J Glob Oncol. 2015 Sep 23;1(1):11-22. doi: 10.1200/JGO.2015.000877. eCollection 2015 Oct.
- Background: PubMed 28325242Grover S, Gudi S, Gandhi AK, Puri PM, Olson AC, Rodin D, Balogun O, Dhillon PK, Sharma DN, Rath GK, Shrivastava SK, Viswanathan AN, Mahantshetty U. Radiation Oncology in India: Challenges and Opportunities. Semin Radiat Oncol. 2017 Apr;27(2):158-163. doi: 10.1016/j.semradonc.2016.11.007. Epub 2016 Nov 14.
- Background: PubMed 25337139Banerjee S, Mahantshetty U, Shrivastava S. Brachytherapy in India - a long road ahead. J Contemp Brachytherapy. 2014 Oct;6(3):331-5. doi: 10.5114/jcb.2014.45761. Epub 2014 Oct 6.
- Background: PubMed 26816503Gandhi AK, Sharma DN, Julka PK, Rath GK. Attitude and practice of brachytherapy in India: a study based on the survey amongst attendees of Annual Meeting of Indian Brachytherapy Society. J Contemp Brachytherapy. 2015 Dec;7(6):462-8. doi: 10.5114/jcb.2015.55666. Epub 2015 Nov 17.
- Background: PubMed 30085892Mittal P, Chopra S, Pant S, Mahantshetty U, Engineer R, Ghosh J, Gupta S, Ghadi Y, Menachery S, Swamidas J, Gurram L, Shrivastava SK. Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy? J Glob Oncol. 2018 Jul;4:1-9. doi: 10.1200/JGO.18.00028.
- Background: PubMed 29280456Mahantshetty U, Krishnatry R, Hande V, Jamema S, Ghadi Y, Engineer R, Chopra S, Gurram L, Deshpande D, Shrviastava S. Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):608-617. doi: 10.1016/j.ijrobp.2017.06.010. Epub 2017 Jun 20.
- Background: PubMed 27335496Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. J ICRU. 2013 Apr;13(1-2):NP. doi: 10.1093/jicru/ndw027. No abstract available.
- Individual participant dataSharing planned: Undecided
Related trials for Cervical Cancer Screening
Active, not recruiting
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Cervical Cancer Screening
Recruiting
Developing and Implementing HPV SCREENED
Cervical Cancer Screening, Human Papilloma Virus
Not yet recruiting
Cancer Awareness Among Syrian Migrants
Breast Cancer Screening, Cervical Cancer Screening
Recruiting
Effectiveness of an eHealth Intervention for Uptake of Cervical Cancer Screening in Hispanic Women
Cervical Cancer Screening
Not yet recruiting
Cervical Cancer Awareness Education to Aid Confidence and Screening upTake (ACT): A Pilot Randomised Control Trial
Anxiety, Cervical Cancer Screening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr. Supriya Chopra, MD principal investigator
ACTREC, Tata Memorial Centre, Navi Mumbai India
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Cancer Screening and Gynecologic Cancers, run by Tata Memorial Hospital at 2 sites in India.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr. Supriya Chopra, MD (9930958309, supriyasastri@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
report on institutional compliance to National Cancer Grid cervical cancer guidelines for chemo-radiation. (time frame: 3 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07290972, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026; AzTrials last refreshed its copy on 26 Oct 2026.